# GPN Vaccines Closes Fully Subscribed US$10 Million Private Placement to Advance Gamma-PN™, a Potentially First-in-Class Serotype-Independent Pneumococcal Vaccine

- Source: PR Newswire M&A
- Published: 2026-11-02T11:30:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/gpn-vaccines-closes-fully-subscribed-us10-million-private-placement-to-advance-gamma-pn-a-potentially-first-in-class-serotype-independent-pneumococcal-vaccine-302925317.html
- Canonical: https://groundlevelnews.com/story/gpn-vaccines-closes-fully-subscribed-us-10-million-private-placement-t-eae97c/

Proceeds to support Phase 2-enabling activities for Gamma-PN, including cGMP manufacturing, expansion of the Company's OPA-testing capabilities and planned submission of an IND to the FDA NEW YORK and ADELAIDE, Australia, Nov. 2, 2026 /PRNewswire/ -- GPN Vaccines, Inc., a clinical-stage...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._